Autolomous and Vineti align to help cell and gene therapy developers scale-up

By Jane Byrne contact

- Last updated on GMT

© GettyImages/metamorworks
© GettyImages/metamorworks

Related tags: cell and gene therapy, NHS

Announcing a new partnership, Autolomous and Vineti say they are integrating their technology to ensure scalability when cell and gene therapies become standard of care.

Their technology tie-up is aimed at delivering effective end to end supply chain management for that biopharma sector, with the parties looking to provide a unified single digital solution for CGT developers that can be used from the collection of patient starting material through to the manufacturing and delivery of therapies.

They say this will be particularly useful when there is a plethora of supply chain partners and patient samples involved. 

Autolomous Ltd develops critical manufacturing management systems for cell and gene (CGT) therapies, leveraging emerging technologies such as Distributed Ledger Technology (DLT) and Internet of Things (IoT) to ensure compliance with current and future regulatory requirements. It is supporting a range of advanced therapies, from CAR-T, TIL, allogeneic NK, IPSC and dendritic-cell based treatments.

Vineti, co-founded by GE and the Mayo Clinic, provides digital enterprise platforms for CGT supply chains, designed to integrate logistics, supply chain management, manufacturing, and clinical data for personalized therapies.

The alliance will merge Autolomous’ critical manufacturing management systems with Vineti’s Personalized Therapy Management (PTM) platform. 

“This will enable both parties to create a seamless end-to-end CGT delivery pathway including critical inbound and outbound manufacturing value processes.

“The result will be an increase in the visibility and dynamic exchange of information to and from stakeholders across the CGT value chain, ensuring they can react to unpredictable variables related to working on biological processes.

“Furthermore, the integration of the technologies will enable scaling up of manufacturing by increasing transparency, compliance and auditability whilst delivering significant savings in time and resources from efficiency gains.”

NHS focused project

Autolomous says its long-term strategy is to provide support across the entire CGT value chain.

The company was part of an alliance awarded a £1m (US$1.3m) grant from UK Research and Innovation (UKRI) in July to enhance to enhance the scheduling and manufacturing of advanced therapy medicinal products (ATMPs) within the UK’s NHS.

Autolomous is collaborating in the project with, among others, the University of Birmingham and teams at the University Hospitals Birmingham NHS Foundation Trust (UHB).

The company said studies it has undertaken have shown the limited planning and investment by either public or private sectors into the management of data and manufacturing documents to support the optimization and maximization of ATMP manufacturing facilities and capacities.

“This project will enable Autolomous to provide a wide scale demonstration of its solutions integrating critical manufacturing data into the ATMP ordering system of a national healthcare provider,”​ commented CEO, Alexander Seyf, at the time.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Related suppliers

Follow us

Products

View more

Webinars